ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Q1 2019 Earnings Conference Call Transcript
May 08, 2019 • 04:30 pm ET
Good afternoon, ladies and gentlemen, and welcome to the Ziopharm Oncology First Quarter 2019 Results Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions)
I would now like to turn the conference over to your host, Mr. Chris Taylor, Vice President, Investor Relations, Corporate Communications. Sir, you may begin.
Thank you, Bridget. Good afternoon. Welcome to the Ziopharm Oncology conference call and webcast to review results for the first quarter of 2019. This afternoon, we filed our 10-Q and issued our Q1 news release, both of which are available in the Investors Section of our website, ziopharm.com. During the course of this call, the Company will make forward-looking statements, including statements regarding the potential therapeutic candidates in our development pipeline, regulatory status, financial information and business trends. Forward-looking statements are subject to numerous risks and uncertainties, as described in our 10-Q and within other filings that we may make with the SEC.
Participating on the call today are Dr. Laurence Cooper, CEO of Ziopharm; and Dr. David Mauney, our company President. Each will provide commentary and we'll open the call for Q&A.
Now I'd like to turn the call over to Dr. Mauney. Good afternoon, David.
Yeah, thanks, Chris, and welcome aboard here at Ziopharm, and thank you for everyone. Thank you, everyone for joining us today on the call. We are pleased to speak with you this afternoon to provide an overview of results for the first quarter of 2019 to provide you an update on our core programs and to highlight value-creating milestones we expect for this year. We extend a special welcome to those of you who have taken a new look at Ziopharm over the last few months. We benefit now from an increasingly strong and supportive base of shareholders and we are pleased to see evidence of new support this year. We also welcome two new analyst on this call, each of them initiated coverage of Ziopharm in recent weeks.
We began 2019 with significant corporate momentum. In addition to a reinforced corporate structure and balance sheet, we are now well-positioned to achieve multiple-critical and value-driving milestones this year, including being in the clinic with all of our pillar programs, namely TCR-T, CAR-T and Controlled IL-12. We are pleased to report that all of the important clinical milestones articulated on our year end call are on track and today, we reaffirmed our timelines for attaining those events. With these milestones essentially upon us, the table is set for what we believe will be very a strong balance of the year. To accomplish our goals, we have established strong partnerships with those we think are the most recognized leaders in our field.
For our solid tumor TCR program, our external clinical lead is Dr. Steven Rosenberg, Chief of the Surgery Branch and Head of the Tumor Immunology Section at the NCI. We spent increasing amounts of time at the